Clinical trials are a hugely complex enterprise that depend on the expertise, organization and dedication of many scientists, engineers, clinicians, project managers and their teams, strong collaboration with doctors, nurses, hospitals and their clinical teams and collaborations with governments and health care regulators. Most importantly, clinical trials rely on the participation of volunteers, patients, caregivers and we hope these trials will lead to the advancement of new medicines. What we do is complex but is also an amazing opportunity to make a difference in the
Today, we sit at the crossroads of important changes in the healthcare ecosystem. We embrace new science, digitization and the evolving healthcare environment reshaping our industry and existing business models. As Janssen’s Global Regulatory Affairs (GRA) team, we recognize the key role we play in empowering such innovation. We promote a culture of "here’s how we can." We have a mindset of co-creation and an ambitious strategy to deliver transformational medicines.
The cancer research landscape looked vastly different when I began my career almost 15 years ago.
Those of us who work in drug development, we don’t all have the same journey to our profession. Some of us were brilliant at math and science, some desired to be challenged daily and others wanted to bring our creativity into the lab. Though our paths to Janssen differ, there is one thing that binds us together, and that is the reason why we do what we do: the patients and their families.
Turning Data into Measurable, Viable Results
Racial and social justice are not just buzzwords, they are crucial elements of public health. As Head of Diversity, Equity, and Inclusion (DE&I), Pharmaceuticals, R&D and Global External Innovation at Janssen, my journey and passion for transforming the culture of healthcare has been deeply influenced by my personal experiences.